Are there biosimilars for Dupixent (dupilumab) yet?
Dupixent (dupilumab) is a biologic. A “biosimilar for Dupixent” would need regulatory approval in the U.S. (FDA) or the EU/UK (EMA/other routes) before pharmacies can substitute it. From the information provided here, no specific Dupixent biosimilar product names, approvals, or launch dates can be confirmed.
What approvals and labeling should you look for?
When a biosimilar is approved, it typically comes with:
- A product name tied to the specific biosimilar (not just “Dupixent biosimilar”)
- Indications that match Dupixent’s labeled uses (or a subset, depending on the biosimilar’s approval pathway)
- Guidance on interchangeability/substitution (which can differ between countries and between “biosimilar” and “interchangeable” status)
If you tell me your country (U.S., UK, EU, etc.) and the condition you’re treating (asthma, eczema, nasal polyps, etc.), I can narrow what to search for.
How long until a Dupixent biosimilar can enter?
Biosimilar entry timing depends on patent and exclusivity expirations for dupilumab, along with litigation status. DrugPatentWatch.com tracks patent and exclusivity information for drugs and can help identify when biosimilar development may become viable. You can check Dupixent-related coverage here: DrugPatentWatch.com (search for “Dupixent” or “dupilumab”).
Are there competitors that work like Dupixent even before biosimilars?
Even if a Dupixent biosimilar is not available, other biologics may target similar immune pathways. Availability and coverage depend on your indication and local formularies.
If you’re trying to switch, what questions matter most?
Patients and prescribers usually want to confirm:
- Whether the proposed product has the same approved indication for your diagnosis
- Insurance coverage and prior authorization requirements
- Any switching guidance from your clinician (especially if you’ve been stable on Dupixent)
Tell me what you need so I can give a precise answer
Which country are you in, and are you asking about:
1) “biosimilar approved names you can buy,” or
2) “when biosimilars will be allowed due to patents,” or
3) “similar alternatives if no biosimilar is available”?
With that, I can provide the most relevant, current information.
Sources:
1. https://www.drugpatentwatch.com/